Rocket Pharmaceuticals, Inc. Additional Paid in Capital
Rocket Pharmaceuticals, Inc. (RCKT) had Additional Paid in Capital of $1.73 billion as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapital · last filed 2026-08-10
- 2026-06-30: Additional Paid in Capital $1.73B.
- 2026-03-31: Additional Paid in Capital $1.73B.
- 2025-12-31: Additional Paid in Capital $1.72B.
- 2025-09-30: Additional Paid in Capital $1.71B.
| Period end | Additional Paid in Capital | Additional Paid in Capital as first filed |
|---|---|---|
| 2026-06-30 | $1.73B 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $1.73B 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $1.72B 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $1.71B 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $1.70B 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $1.69B 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $1.68B 10-K · filed 2026-02-26 | |
| 2024-09-30 | $1.49B 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $1.48B 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $1.46B 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $1.45B 10-K · filed 2025-02-27 | |
| 2023-09-30 | $1.44B 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $1.24B 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $1.23B 10-Q · filed 2023-05-05 | |
| 2022-12-31 | $1.20B 10-K · filed 2024-02-27 | |
| 2022-09-30 | $1.01B 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $977.10M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $952.50M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $946.15M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $932.78M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $886.43M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $842.48M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $825.79M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $503.22M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $498.59M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $493.81M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $489.93M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $394.93M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $392.20M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $302.04M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $300.25M 10-K · filed 2020-03-06 | |
| 2018-09-30 | $221.98M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $219.22M 10-Q · filed 2018-08-14 | |
| 2018-03-31 | $216.44M 10-Q · filed 2018-05-11 | |
| 2017-12-31 | $5.34M 10-K · filed 2019-03-08 | $5.41M 10-Q · filed 2018-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |